TPEX:1799

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Easywell Biomedicals

Market Cap

NT$2.3b

Last Updated

2021/06/18 08:49 UTC

Data Sources

Company Financials

Executive Summary

Easywell Biomedicals, Inc., a biopharmaceutical and medical device company, develops and commercializes medical devices, drug substances, and pharmaceutical dosage forms in Taiwan and internationally. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Easywell Biomedicals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1799 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 1799's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-3.3%

1799

2.8%

TW Medical Equipment

1.3%

TW Market


1 Year Return

-26.4%

1799

-5.1%

TW Medical Equipment

48.5%

TW Market

Return vs Industry: 1799 underperformed the TW Medical Equipment industry which returned -5.9% over the past year.

Return vs Market: 1799 underperformed the TW Market which returned 48.1% over the past year.


Shareholder returns

1799IndustryMarket
7 Day-3.3%2.8%1.3%
30 Day-3.5%12.6%8.1%
90 Day0.9%13.9%8.0%
1 Year-26.4%-26.4%-2.9%-5.1%53.3%48.5%
3 Year-6.8%-6.8%16.3%6.6%75.9%55.7%
5 Year-42.1%-42.1%8.6%-5.6%140.8%97.9%

Long-Term Price Volatility Vs. Market

How volatile is Easywell Biomedicals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Easywell Biomedicals undervalued compared to its fair value and its price relative to the market?

3.21x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1799's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1799's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1799 is unprofitable, so we can't compare its PE Ratio to the TW Medical Equipment industry average.

PE vs Market: 1799 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1799's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1799 is overvalued based on its PB Ratio (3.2x) compared to the TW Medical Equipment industry average (2.1x).


Future Growth

How is Easywell Biomedicals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Easywell Biomedicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Easywell Biomedicals performed over the past 5 years?

5.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1799 is currently unprofitable.

Growing Profit Margin: 1799 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1799 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.4% per year.

Accelerating Growth: Unable to compare 1799's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1799 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.9%).


Return on Equity

High ROE: 1799 has a negative Return on Equity (-18%), as it is currently unprofitable.


Financial Health

How is Easywell Biomedicals's financial position?


Financial Position Analysis

Short Term Liabilities: 1799's short term assets (NT$320.9M) exceed its short term liabilities (NT$45.7M).

Long Term Liabilities: 1799's short term assets (NT$320.9M) exceed its long term liabilities (NT$286.9M).


Debt to Equity History and Analysis

Debt Level: 1799 is debt free.

Reducing Debt: 1799 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1799 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 1799 has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 6.1% each year.


Dividend

What is Easywell Biomedicals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1799's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1799's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1799's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1799's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 1799 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1799's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Easywell Biomedicals has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.8%.


Top Shareholders

Company Information

Easywell Biomedicals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Easywell Biomedicals, Inc.
  • Ticker: 1799
  • Exchange: TPEX
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: NT$2.279b
  • Shares outstanding: 139.38m
  • Website: https://www.easywellbio.com

Location

  • Easywell Biomedicals, Inc.
  • No.10, Yanfa 2nd Road
  • Hsinchu Science Park
  • Hsinchu City
  • 30076
  • Taiwan

Listings


Biography

Easywell Biomedicals, Inc., a biopharmaceutical and medical device company, develops and commercializes medical devices, drug substances, and pharmaceutical dosage forms in Taiwan and internationally. The ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/18 08:49
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.